0000950170-24-082485.txt : 20240709 0000950170-24-082485.hdr.sgml : 20240709 20240709173003 ACCESSION NUMBER: 0000950170-24-082485 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240705 FILED AS OF DATE: 20240709 DATE AS OF CHANGE: 20240709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Michaelson Jennifer CENTRAL INDEX KEY: 0001838061 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 241108199 MAIL ADDRESS: STREET 1: C/O CULLINAN MANAGEMENT, INC. STREET 2: ONE MAIN STREET SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Therapeutics, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, Inc. DATE OF NAME CHANGE: 20210225 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 ownership.xml 4 X0508 4 2024-07-05 0001789972 Cullinan Therapeutics, Inc. CGEM 0001838061 Michaelson Jennifer C/O CULLINAN THERAPEUTICS, INC. ONE MAIN STREET, SUITE 1350 CAMBRIDGE MA 02142 false true false false Chief Scientific Officer true Common Stock 2024-07-05 4 S false 8000 16.33 D 123942 D Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.97 to $16.77. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Jacquelyn Sumer, Attorney-in-Fact 2024-07-09